Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Pfizer-BioNTech sign on to provide 200 million more COVID-19 vaccine doses to the U.S.
Lumos delays key hormone deficiency readout as COVID bites
Tenet Healthcare: Volumes recovery unthreatened by resurging COVID-19
Medical practices working with startup Aledade saw big financial wins in 2020 despite COVID-19 turmoil
Happify Health debuts digital app to tackle both anxiety and depression
Lumen plots site at nearby Seattle bakery as it ramps up production of algae-based biologics
COVID-19 tracker: Pfizer, BioNTech ink another US supply deal; J&J shot nabs safety backing from CDC experts
Fierce Pharma Asia—Junshi's mRNA JV; Novartis' China business; Roche's Ronapreve COVID nod in Japan

Featured Story

Pfizer-BioNTech sign on to provide 200 million more COVID-19 vaccine doses to the U.S.

By Kevin Dunleavy

Pfizer and BioNTech revealed a new deal with the United States to deliver 200 million additional doses of their COVID-19 vaccine. The agreement brings the companies' total supply to the U.S. to 500 million. The doses are to be provided in two batches, with the second by the end of April 2022.

Lumos delays key hormone deficiency readout as COVID bites

By Nick Paul Taylor

Lumos Pharma has delayed top-line data from its phase 2 pediatric growth hormone deficiency (PGHD) trial to the second half of 2023. The biotech blamed the delay on the impact of COVID-19 restrictions on the pace of site initiation and enrollment, particularly at sites outside of the U.S.

Tenet Healthcare: Volumes recovery unthreatened by resurging COVID-19

By Dave Muoio

The Dallas-based company raised its guidance for the remainder of 2021 after seeing higher profits, revenues and volumes compared to last year and last quarter. Executives also noted that the system is prepared for a potential uptick in COVID-19 and don't expect rising cases to impact recovery.

Medical practices working with startup Aledade saw big financial wins in 2020 despite COVID-19 turmoil

By Heather Landi

Aledade's accountable care organizations not only survived the financial turmoil of the COVID-19 pandemic but thrived, thanks to huge savings increases. Aledade CEO Farzad Mostashari spoke with Fierce Healthcare about why the startup's model spelled success for primary care docs during a challenging year.

Happify Health debuts digital app to tackle both anxiety and depression

By Conor Hale

The prescription Ensemble app includes courses for daily skills and coping habits as well as a digital coach named Anna that provides content from psychologists and psychotherapists.

Lumen plots site at nearby Seattle bakery as it ramps up production of algae-based biologics

By Fraiser Kansteiner

Lumen has snagged the lease to a former Seattle bakery that it will soon use to make large volumes of biologics grown in the popular food algae spirulina. The plan for now is to boost supply ahead of Lumen's upcoming clinical trials, though the site could potentially be used for commercial production in the future, Brian Finrow, co-founder and CEO at Lumen, said in an interview.

COVID-19 tracker: Pfizer, BioNTech ink another US supply deal; J&J shot nabs safety backing from CDC experts

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Pfizer and vaccine partner BioNTech have inked another supply deal with the U.S. worth 200 million doses. A key CDC safety group backed Johnson & Johnson's single-shot vaccine following fresh safety concerns. And more headlines.

Fierce Pharma Asia—Junshi's mRNA JV; Novartis' China business; Roche's Ronapreve COVID nod in Japan

By Angus Liu

Junshi Biosciences has formed a joint venture to develop mRNA drugs and vaccines. Novartis recorded strong growth for its China business in the second quarter. Roche wins global-first full nod for COVID-19 antibody combo Ronapreve in Japan. And more.

COVID-19 Tracker